IBD
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study).
Clinical takeawayConsider carotegrast methyl for patients with ulcerative colitis who have an inadequate response to 5-ASA, particularly if symptom improvement is a priority. Monitor for response at 8 weeks and consider continuing treatment up to 16 weeks for further symptom improvement. Be aware of adverse drug reactions, which occurred in 15.8% of patients.
What it foundCarotegrast methyl achieved PRO-2-defined response and remission rates of 57.8% and 43.3% at week 8, and 58.9% and 50.0% at end of treatment (median duration: 83.5 days).
ContextThis study provides real-world evidence supporting carotegrast methyl as an effective option for patients with ulcerative colitis who have an inadequate response to 5-ASA, aligning with its use in clinical practice but offering new data on timing and cumulative benefits.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Hirai F … Hisamatsu T · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗